Publication - Consultation paper

Review of Lung Cancer Quality Performance Indicators: consultation

Published: 14 Nov 2016

A consultation on the revised Lung Cancer Quality Performance Indicators (QPIs), which were revised following a formal review.

Review of Lung Cancer Quality Performance Indicators: consultation
Appendix 1: QPI Development Process

12. Appendices

Appendix 1: QPI Development Process

Preparatory Work and Scoping

The preparatory work involved the development of a structured briefing paper by Healthcare Improvement Scotland. This paper took account of existing, high quality, clinical guidance and provided a basis for the development of QPIs.

The scope for development of lung cancer QPIs and a search narrative were defined and agreed by the Lung Cancer QPI Development Group. The table below shows the final search criteria used in the literature search.



Lung carcinomas

Lung sarcomas

Adults only

Date: 2005 or later

Topics: diagnosis, staging, management of non-metastatic (organ confined or locally advanced) and metastatic (advanced) disease, follow up

Topics: prevention, screening, palliative/end of life care

Table 1 - Lung Cancer Search Criteria

A systematic search was carried out by Healthcare Improvement Scotland using selected websites and two primary medical databases to identify national and international guidelines.

Thirty-four guidelines were appraised for quality using the AGREE II instrument. The instrument assesses the methodological rigour and precision used when developing a guideline. Seventeen of the guidelines were not recommended for use. Five of the guidelines were recommended for use and six recommended for use with modifications.

Indicator Development

The Lung Cancer QPI Development Group defined evidence based, measurable indicators with a clear focus on improving the quality and outcome of care provided.

The Group developed QPIs using the clinical recommendations set out in the briefing paper as a base, ensuring all indicators met the following criteria:

  • Overall importance - does the indicator address an area of clinical importance that would significantly impact on the quality and outcome of care delivered?
  • Evidence based - is the indicator based on high quality clinical evidence?
  • Measurability - is the indicator measurable i.e. are there explicit requirements for data measurement and are the required data items accessible and available for collection?

Engagement Process

A wide clinical and public engagement exercise was undertaken as part of development in 2011 where the Lung Cancer QPIs, along with accompanying draft minimum core dataset and measurability specifications, were made available on the Scottish Government website.

During the engagement period clinical and management colleagues from across NHSScotland, patients affected by lung cancer and the wider public were given the opportunity to influence the development of Lung Cancer QPIs.

Draft documentation was circulated widely to professional groups, health service staff, voluntary organisations and individuals for comment and feedback.

Following the engagement period all comments and responses received were reviewed by the Lung Cancer QPI Development Group and used to produce and refine the final indicators.